['anemia', 'renal insufficiency, chronic']
['bay85-3934', 'placebo']

        Inclusion Criteria:

          -  Women without childbearing potential

          -  Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD)
             at screening

          -  Estimated glomerular filtration rate of < 60 mL/min/1.73 m2 (Modification of Diet in
             Renal Disease [MDRD] or the formula according to Matsuo, et al)

          -  Not on dialysis and not expected to begin dialysis during the treatment period of the
             study (at least 16 weeks from randomization)

          -  Not treated with any erythropoiesis-stimulating agent (ESA) within 8 weeks before
             randomization

          -  Mean screening Hb concentration </= 10.5 g/dL

          -  Body weight of 45 kg to 125 kg, inclusive, at screening

        Exclusion Criteria:

          -  Subjects with significant acute or chronic bleeding, such as overt gastrointestinal
             bleeding

          -  Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in
             remission

          -  Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell
             carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively
             treated > 3 years prior to randomization

          -  Subjects treated with any ESA within the 8 weeks before randomization

          -  Red blood cell (RBC) containing transfusion within the 8 weeks before randomization

          -  History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial
             infarction, stroke, transient ischemic attack, deep vein thrombosis, pulmonary
             embolism) within the last 6 months from initial screening visit

          -  Severe rhythm or conduction disorders (e.g., HR < 50 or > 110 bpm, atrial flutter,
             prolonged QT > 500 msec, third degree atrioventricular [AV] block)

          -  New York Heart Association Class III or IV congestive heart failure

          -  Severe hepatic insufficiency (defined as alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] > 3 x the upper limit of normal [ULN], total bilirubin > 2
             mg/dL, or Child-Pugh B and C) or active hepatitis, in the investigator's opinion
      